CYP2C19 gene polymorphism in Ningxia

Background Poor metabolizer (PM) status of CYP2C19 can be a predisposing factor for developing gastric cancer in  H. pylori -infected patients. It is unclear whether PM status of CYP2C19 can also be a potential factor for  H.pylori  infection in healthy people. Methods We used high-throughput sequen...

Full description

Saved in:
Bibliographic Details
Published inPharmacological reports Vol. 75; no. 3; pp. 705 - 714
Main Authors Yang, Zhen, Xie, Yunqian, Zhang, Daya, Zou, Yan, Li, Ximei, Chen, Runxiang, Zhang, Xiaodong, Chen, Shiju, Bai, Feihu
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.06.2023
Subjects
Drug Safety and Pharmacovigilance
Medicine
Pharmacotherapy
Pharmacy
CYP2C19
Infectious disease
Polymorphism
H. pylori
Online AccessGet full text

Cover

Abstract Background Poor metabolizer (PM) status of CYP2C19 can be a predisposing factor for developing gastric cancer in  H. pylori -infected patients. It is unclear whether PM status of CYP2C19 can also be a potential factor for  H.pylori  infection in healthy people. Methods We used high-throughput sequencing to detect single nucleotide polymorphisms (SNPs) at just three loci, rs4244285 (CYP2C19*2), rs4986893 (CYP2C19*3) and rs12248560 (CYP2C19*17), to identify the exact CYP2C19 alleles corresponding to the mutated sites. We determined CYP2C19 genotypes of 1050 subjects from 5 cities of Ningxia from September 2019 to September 2020 and evaluated the potential correlation between H.pylori and CYP2C19 gene polymorphisms. Clinical data were analyzed using χ2 tests. Results The frequency of CYP2C19*17 in Hui (3.7%) was higher as compared to Han (1.4%) in Ningxia ( p  = 0.001). The frequency of CYP2C19*1/*17 of Hui (4.7%) was higher as compared to Han (1.6%) in Ningxia ( p  = 0.004). The frequency of CYP2C19*3/*17 of Hui (1%) was higher as compared to Han (0%) in Ningxia ( p  = 0.023). The frequencies of alleles ( p  = 0.142) and genotypes ( p  = 0.928) were not found to be significantly different among the different BMI groups. The frequencies of four alleles between  H. pylori  positive and negative groups were not found to be statistically different ( p  = 0.794). The frequencies of the different genotypes between  H. pylori  positive and negative groups were not statistically different ( p  = 0.974), and no statistical difference was observed between the different metabolic phenotypes ( p  = 0.494). Conclusion There were regional differences observed in CYP2C19*17 distribution in Ningxia. The frequency of CYP2C19*17 in Hui was higher than in Han of Ningxia. No significant relationship was found between CYP2C19 gene polymorphism and susceptibility to H. pylori infection.
AbstractList Poor metabolizer (PM) status of CYP2C19 can be a predisposing factor for developing gastric cancer in H. pylori-infected patients. It is unclear whether PM status of CYP2C19 can also be a potential factor for H.pylori infection in healthy people.BACKGROUNDPoor metabolizer (PM) status of CYP2C19 can be a predisposing factor for developing gastric cancer in H. pylori-infected patients. It is unclear whether PM status of CYP2C19 can also be a potential factor for H.pylori infection in healthy people.We used high-throughput sequencing to detect single nucleotide polymorphisms (SNPs) at just three loci, rs4244285 (CYP2C19*2), rs4986893 (CYP2C19*3) and rs12248560 (CYP2C19*17), to identify the exact CYP2C19 alleles corresponding to the mutated sites. We determined CYP2C19 genotypes of 1050 subjects from 5 cities of Ningxia from September 2019 to September 2020 and evaluated the potential correlation between H.pylori and CYP2C19 gene polymorphisms. Clinical data were analyzed using χ2 tests.METHODSWe used high-throughput sequencing to detect single nucleotide polymorphisms (SNPs) at just three loci, rs4244285 (CYP2C19*2), rs4986893 (CYP2C19*3) and rs12248560 (CYP2C19*17), to identify the exact CYP2C19 alleles corresponding to the mutated sites. We determined CYP2C19 genotypes of 1050 subjects from 5 cities of Ningxia from September 2019 to September 2020 and evaluated the potential correlation between H.pylori and CYP2C19 gene polymorphisms. Clinical data were analyzed using χ2 tests.The frequency of CYP2C19*17 in Hui (3.7%) was higher as compared to Han (1.4%) in Ningxia (p = 0.001). The frequency of CYP2C19*1/*17 of Hui (4.7%) was higher as compared to Han (1.6%) in Ningxia (p = 0.004). The frequency of CYP2C19*3/*17 of Hui (1%) was higher as compared to Han (0%) in Ningxia (p = 0.023). The frequencies of alleles (p = 0.142) and genotypes (p = 0.928) were not found to be significantly different among the different BMI groups. The frequencies of four alleles between H. pylori positive and negative groups were not found to be statistically different (p = 0.794). The frequencies of the different genotypes between H. pylori positive and negative groups were not statistically different (p = 0.974), and no statistical difference was observed between the different metabolic phenotypes (p = 0.494).RESULTSThe frequency of CYP2C19*17 in Hui (3.7%) was higher as compared to Han (1.4%) in Ningxia (p = 0.001). The frequency of CYP2C19*1/*17 of Hui (4.7%) was higher as compared to Han (1.6%) in Ningxia (p = 0.004). The frequency of CYP2C19*3/*17 of Hui (1%) was higher as compared to Han (0%) in Ningxia (p = 0.023). The frequencies of alleles (p = 0.142) and genotypes (p = 0.928) were not found to be significantly different among the different BMI groups. The frequencies of four alleles between H. pylori positive and negative groups were not found to be statistically different (p = 0.794). The frequencies of the different genotypes between H. pylori positive and negative groups were not statistically different (p = 0.974), and no statistical difference was observed between the different metabolic phenotypes (p = 0.494).There were regional differences observed in CYP2C19*17 distribution in Ningxia. The frequency of CYP2C19*17 in Hui was higher than in Han of Ningxia. No significant relationship was found between CYP2C19 gene polymorphism and susceptibility to H. pylori infection.CONCLUSIONThere were regional differences observed in CYP2C19*17 distribution in Ningxia. The frequency of CYP2C19*17 in Hui was higher than in Han of Ningxia. No significant relationship was found between CYP2C19 gene polymorphism and susceptibility to H. pylori infection.
Poor metabolizer (PM) status of CYP2C19 can be a predisposing factor for developing gastric cancer in H. pylori-infected patients. It is unclear whether PM status of CYP2C19 can also be a potential factor for H.pylori infection in healthy people. We used high-throughput sequencing to detect single nucleotide polymorphisms (SNPs) at just three loci, rs4244285 (CYP2C19*2), rs4986893 (CYP2C19*3) and rs12248560 (CYP2C19*17), to identify the exact CYP2C19 alleles corresponding to the mutated sites. We determined CYP2C19 genotypes of 1050 subjects from 5 cities of Ningxia from September 2019 to September 2020 and evaluated the potential correlation between H.pylori and CYP2C19 gene polymorphisms. Clinical data were analyzed using χ2 tests. The frequency of CYP2C19*17 in Hui (3.7%) was higher as compared to Han (1.4%) in Ningxia (p = 0.001). The frequency of CYP2C19*1/*17 of Hui (4.7%) was higher as compared to Han (1.6%) in Ningxia (p = 0.004). The frequency of CYP2C19*3/*17 of Hui (1%) was higher as compared to Han (0%) in Ningxia (p = 0.023). The frequencies of alleles (p = 0.142) and genotypes (p = 0.928) were not found to be significantly different among the different BMI groups. The frequencies of four alleles between H. pylori positive and negative groups were not found to be statistically different (p = 0.794). The frequencies of the different genotypes between H. pylori positive and negative groups were not statistically different (p = 0.974), and no statistical difference was observed between the different metabolic phenotypes (p = 0.494). There were regional differences observed in CYP2C19*17 distribution in Ningxia. The frequency of CYP2C19*17 in Hui was higher than in Han of Ningxia. No significant relationship was found between CYP2C19 gene polymorphism and susceptibility to H. pylori infection.
Background Poor metabolizer (PM) status of CYP2C19 can be a predisposing factor for developing gastric cancer in  H. pylori -infected patients. It is unclear whether PM status of CYP2C19 can also be a potential factor for  H.pylori  infection in healthy people. Methods We used high-throughput sequencing to detect single nucleotide polymorphisms (SNPs) at just three loci, rs4244285 (CYP2C19*2), rs4986893 (CYP2C19*3) and rs12248560 (CYP2C19*17), to identify the exact CYP2C19 alleles corresponding to the mutated sites. We determined CYP2C19 genotypes of 1050 subjects from 5 cities of Ningxia from September 2019 to September 2020 and evaluated the potential correlation between H.pylori and CYP2C19 gene polymorphisms. Clinical data were analyzed using χ2 tests. Results The frequency of CYP2C19*17 in Hui (3.7%) was higher as compared to Han (1.4%) in Ningxia ( p  = 0.001). The frequency of CYP2C19*1/*17 of Hui (4.7%) was higher as compared to Han (1.6%) in Ningxia ( p  = 0.004). The frequency of CYP2C19*3/*17 of Hui (1%) was higher as compared to Han (0%) in Ningxia ( p  = 0.023). The frequencies of alleles ( p  = 0.142) and genotypes ( p  = 0.928) were not found to be significantly different among the different BMI groups. The frequencies of four alleles between  H. pylori  positive and negative groups were not found to be statistically different ( p  = 0.794). The frequencies of the different genotypes between  H. pylori  positive and negative groups were not statistically different ( p  = 0.974), and no statistical difference was observed between the different metabolic phenotypes ( p  = 0.494). Conclusion There were regional differences observed in CYP2C19*17 distribution in Ningxia. The frequency of CYP2C19*17 in Hui was higher than in Han of Ningxia. No significant relationship was found between CYP2C19 gene polymorphism and susceptibility to H. pylori infection.
Author Yang, Zhen
Zou, Yan
Zhang, Daya
Zhang, Xiaodong
Bai, Feihu
Chen, Runxiang
Xie, Yunqian
Li, Ximei
Chen, Shiju
Author_xml – sequence: 1
  givenname: Zhen
  orcidid: 0000-0001-8701-7259
  surname: Yang
  fullname: Yang, Zhen
  organization: Department of Infectious Disease, People’s Hospital of Ningxia Hui Autonomous Region
– sequence: 2
  givenname: Yunqian
  surname: Xie
  fullname: Xie, Yunqian
  organization: Department of Gastroenterology, The Second Affiliated Hospital of Hai Nan Medical University, The Gastroenterology Clinical Medical Center of Hainan Province
– sequence: 3
  givenname: Daya
  orcidid: 0000-0001-6133-8919
  surname: Zhang
  fullname: Zhang, Daya
  organization: Graduate School, Hainan Medical University
– sequence: 4
  givenname: Yan
  orcidid: 0000-0003-3379-2369
  surname: Zou
  fullname: Zou, Yan
  organization: The Third School of Clinical Medicine, Ningxia Medical University
– sequence: 5
  givenname: Ximei
  surname: Li
  fullname: Li, Ximei
  organization: The Third School of Clinical Medicine, Ningxia Medical University
– sequence: 6
  givenname: Runxiang
  surname: Chen
  fullname: Chen, Runxiang
  organization: Graduate School, Hainan Medical University
– sequence: 7
  givenname: Xiaodong
  surname: Zhang
  fullname: Zhang, Xiaodong
  organization: Graduate School, Hainan Medical University
– sequence: 8
  givenname: Shiju
  surname: Chen
  fullname: Chen, Shiju
  organization: Graduate School, Hainan Medical University
– sequence: 9
  givenname: Feihu
  orcidid: 0000-0002-1560-6131
  surname: Bai
  fullname: Bai, Feihu
  email: baifeihu_hy@163.com
  organization: Department of Gastroenterology, The Second Affiliated Hospital of Hai Nan Medical University, The Gastroenterology Clinical Medical Center of Hainan Province
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36913175$$D View this record in MEDLINE/PubMed
BookMark eNp9kLtOwzAUQC1URB_wAwwoAwOLwc84GVHFS6qAAQYmy0ns4iqxg51I9O9JSVkYOt3lnKt7zxxMnHcagHOMrjFC4iYyyhiCiFCIEBMU8iMwIyTPIU8zNgEzLCiDGDM0BfMYNwOECeUnYErTHFMs-AxcLj9eyRLnyVo7nbS-3jY-tJ82Nol1ybN162-rTsGxUXXUZ_u5AO_3d2_LR7h6eXha3q5gSZnoYGEKYUpRClUozFklOOKpIAhxo6lgKhVI50prY0hWaVJgpgpemryiBWKcC7oAV-PeNvivXsdONjaWuq6V076Pkogs5Xi4fYde7NG-aHQl22AbFbby77MByEagDD7GoI0sbac6610XlK0lRnIXUY4R5RBR_kaUO5X8U_-2H5ToKMUBdmsd5Mb3wQ25Dlk_50qBcQ
CitedBy_id crossref_primary_10_1038_s41598_024_52540_3
Cites_doi 10.1038/s41431-019-0480-8
10.1007/s12041-015-0477-1
10.1371/journal.pone.0263137
10.1371/journal.pone.0073126
10.1111/j.1365-2125.2004.02144.x
10.1016/j.envint.2021.107046
10.1089/gtmb.2011.0084
10.12659/MSM.905337
10.1007/s005350170029
10.1080/16078454.2022.2121899
10.1038/s41397-020-00196-3
10.1111/j.1572-0241.2003.07427.x
10.1016/j.phrs.2004.01.004
10.1007/s00228-005-0938-1
10.3389/fphar.2021.790832
10.1007/s00228-003-0606-2
10.3892/mmr.2016.4776
10.1007/s00228-002-0425-x
10.1053/cp.1999.v66.100072001
10.1371/journal.pgen.1009323
10.15403/jgld.2014.1121.252.mdr
10.1007/s00228-004-0890-5
10.1038/s41569-021-00566-9
10.3389/fpubh.2021.561873
10.1016/S0009-9236(96)90214-3
10.1111/j.1365-2036.2005.02678.x
10.1006/taap.2001.9294
10.1007/s00228-006-0183-2
10.1038/s41571-021-00509-w
10.7150/ijms.10263
10.7314/APJCP.2014.15.24.10957
10.1016/0009-9236(95)90228-7
10.1016/S0009-9236(98)90070-4
10.1097/00008571-199512000-00004
10.1186/s12920-022-01171-6
10.1097/00008571-199612000-00005
10.4318/tjg.2010.0043
10.1097/00008571-199612000-00008
10.1038/clpt.2012.215
10.1002/cpt.2015
10.1038/s41436-019-0611-1
10.1007/s00535-003-1281-x
10.1111/cts.12692
10.2217/14622416.9.6.691
10.1515/dmdi-2012-0038
10.1001/jama.2009.1232
10.1016/j.bcp.2018.02.020
ContentType Journal Article
Copyright The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
2023. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences.
Copyright_xml – notice: The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
– notice: 2023. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences.
DBID AAYXX
CITATION
NPM
7X8
DOI 10.1007/s43440-023-00473-5
DatabaseName CrossRef
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 2299-5684
EndPage 714
ExternalDocumentID 36913175
10_1007_s43440_023_00473_5
Genre Journal Article
GrantInformation_xml – fundername: Hainan Province Clinical Medical Center
  grantid: 2021818
– fundername: Hainan Provincial Health Industry Research Project
  grantid: 22A200078
– fundername: Hainan Provincial Postgraduate Innovation Research Project
  grantid: Qhyb2022-133
– fundername: the specific research fund of The Innovation Platform for Academicians of Hainan Province
  grantid: 2022136
GroupedDBID ---
--M
0R~
123
29O
2WC
3EA
4.4
406
457
53G
7-5
8P~
AACDK
AACTN
AAEDT
AAHNG
AAIKJ
AAJBT
AAKOC
AALRI
AAOAW
AASML
AATNV
AAUYE
AAXLA
AAXUO
ABAKF
ABECU
ABFRF
ABJNI
ABMQK
ABMZM
ABTEG
ABTKH
ABXDB
ACAOD
ACDAQ
ACDTI
ACGFO
ACGFS
ACHSB
ACPIV
ACZOJ
ADBBV
ADEZE
ADTPH
ADYFF
AEFQL
AEFWE
AEKER
AEMSY
AENEX
AESKC
AFBBN
AFQWF
AFTJW
AGHFR
AGMZJ
AGQEE
AGUBO
AIGIU
AILAN
AITUG
AJOXV
AJZVZ
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMTXH
AMXSW
AMYLF
ANZVX
BAWUL
BGNMA
BLXMC
DIK
DPUIP
E3Z
EBLON
EBS
EJD
F5P
FDB
FEDTE
FIGPU
FIRID
FNLPD
GBLVA
GX1
HH5
HVGLF
IKXTQ
IWAJR
JZLTJ
KOV
LLZTM
M4Y
M~E
NPVJJ
NQJWS
NU0
OAUVE
PT4
RNS
ROL
RSV
SJYHP
SNE
SNPRN
SOHCF
SOJ
SRMVM
SSLCW
SSZ
T5K
TR2
UNMZH
XSB
Y2W
~G-
AAYXX
ABBRH
ABDBE
ABFSG
ACMFV
ACSTC
AEZWR
AFDZB
AFHIU
AFOHR
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
OVT
ABRTQ
NPM
7X8
ID FETCH-LOGICAL-c347t-bfb7fc7c7aba154d7505672005fe374a670e9aeeff28de2b14ab5cf9d3b045573
ISSN 1734-1140
2299-5684
IngestDate Thu Jul 10 18:40:49 EDT 2025
Mon Jul 21 06:03:40 EDT 2025
Thu Apr 24 22:51:24 EDT 2025
Tue Jul 01 00:19:59 EDT 2025
Fri Feb 21 02:43:22 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords CYP2C19
Infectious disease
Polymorphism
H. pylori
Language English
License 2023. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c347t-bfb7fc7c7aba154d7505672005fe374a670e9aeeff28de2b14ab5cf9d3b045573
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-3379-2369
0000-0002-1560-6131
0000-0001-6133-8919
0000-0001-8701-7259
PMID 36913175
PQID 2786516917
PQPubID 23479
PageCount 10
ParticipantIDs proquest_miscellaneous_2786516917
pubmed_primary_36913175
crossref_citationtrail_10_1007_s43440_023_00473_5
crossref_primary_10_1007_s43440_023_00473_5
springer_journals_10_1007_s43440_023_00473_5
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20230600
2023-06-00
2023-Jun
20230601
PublicationDateYYYYMMDD 2023-06-01
PublicationDate_xml – month: 6
  year: 2023
  text: 20230600
PublicationDecade 2020
PublicationPlace Cham
PublicationPlace_xml – name: Cham
– name: Switzerland
PublicationTitle Pharmacological reports
PublicationTitleAbbrev Pharmacol. Rep
PublicationTitleAlternate Pharmacol Rep
PublicationYear 2023
Publisher Springer International Publishing
Publisher_xml – name: Springer International Publishing
References DöhnerHWeiAHLöwenbergBTowards precision medicine for AMLNat Rev Clin Oncol20211895775903400699710.1038/s41571-021-00509-w
MusumbaCOJorgensenASuttonLVan EkerDZhangEO'HaraNCYP2C19*17gain-of-function polymorphism is associated with peptic ulcer diseaseClin Pharmacol Ther20139321952031:CAS:528:DC%2BC3sXhsVars70%3D2326785710.1038/clpt.2012.215
PetrovićJPešićVLauschkeVMFrequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across EuropeEur J Hum Genet202028188943135895510.1038/s41431-019-0480-8
AynaciogluASSachseCBozkurtAKortunaySNacakMSchröderTLow frequency of defec-tive alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish pop-ulationClin Pharmacol Ther1999661851921:CAS:528:DyaK1MXlvVOhsLk%3D1046007210.1053/cp.1999.v66.100072001
HerrlinKMasseleAYJandeMAlmCTybringGAbdiYABantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotypeClin Pharmacol Ther1998643914011:STN:280:DyaK1M%2FhsVGgsg%3D%3D979779610.1016/S0009-9236(98)90070-4
SugimotoMFurutaTShiraiNNakamuraAKajimuraMSugimuraHPoor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infectionAliment Pharmacol Ther20052210103310401:CAS:528:DC%2BD2MXhtlWntrrJ1626897910.1111/j.1365-2036.2005.02678.x
GaoBTanTCaoXPanMYangCWangJRelationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactionsBMC Med Genom2022151231:CAS:528:DC%2BB38XmsFWntLY%3D10.1186/s12920-022-01171-6
PharmGKB. CYP2C19 clinical annotations. 2021. https://www.pharmgkb.org/gene/PA124/clinicalAnnotation.
MasimirembwaCBertilssonLJohanssonIHaslerJAIngelman-SundbergMPheno-typing and genotyping of S-mephenytoin hy-droxylase (cytochrome P450 2C19) in a Shona population of ZimbabweClin Pharmacol Ther1995576566611:STN:280:DyaK2MzgtVChtA%3D%3D778126510.1016/0009-9236(95)90228-7
ZhongZHouJLiBZhangQLiuSLiCAnalysis of CYP2C19 genetic polymorphism in a large ethnic hakka population in Southern ChinaMed Sci Monit201723618661921:CAS:528:DC%2BC1MXosFeltL4%3D29288619575786410.12659/MSM.905337
GaikovitchEACascorbiIMrozikiewiczPMBrockmöllerJFrötschlRKöpkeKPolymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian populationEur J Clin Pharmacol2003593033121:CAS:528:DC%2BD3sXmt1entLo%3D1287916810.1007/s00228-003-0606-2
StajnkoARunkelAAKosjekTSnoj TratnikJMazejDFalnogaIAssessment of susceptibility to phthalate and DINCH exposure through CYP and UGT single nucleotide polymorphismsEnviron Int20221591:CAS:528:DC%2BB38XjvFOju7g%3D3492027710.1016/j.envint.2021.107046
Velmovitsky PE, Bevilacqua T, Alencar P, Cowan D, Morita PP. Convergence of Precision Medicine and Public Health Into Precision Public Health: Toward a Big Data Perspective. Front Public Health. 2021;9:561873.
KappersWAEdwardsRJMurraySBoobisARDiazinon is activated by CYP2C19 in human liverToxicol Appl Pharmacol2001177168761:CAS:528:DC%2BD3MXot12ntrk%3D1170890210.1006/taap.2001.9294
ZhangYDDongQWZhangSHGuFZhangYSongHBEffectiveness of eradication regimen based on the bacterial susceptibility and CYP2C19 genotype in children with refractory Helicobacter pylori infectionZhonghua Er Ke Za Zhi202058141451:STN:280:DC%2BB3MbmvV2ktQ%3D%3D31905475Chinese
SuzukiSMuroishiYNakanishiIOdaYRelationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancerJ Gastroenterol20043932202301:CAS:528:DC%2BD2cXivVaqsr0%3D1506499810.1007/s00535-003-1281-x
JainanWVilaichoneRKEffects of the CYP2C19 genetic polymorphism on gastritis, peptic ulcer disease, peptic ulcer bleeding and gastric cancerAsian Pac J Cancer Prev2014152410957109602560520810.7314/APJCP.2014.15.24.10957
LirongMoInvestigation of the current status of Helicobacter pylori infection in the population of Wuzhong City2019Ningxia and analysis of related factorNingxia Medical University
WangHSongKChenZYuYPoor metabolizers at the cytochrome P450 2C19 loci is at increased risk of developing cancer in Asian populationsPLoS ONE2013881:CAS:528:DC%2BC3sXhsVWhtrjO24015291375491110.1371/journal.pone.0073126
HallingJPetersenMSDamkierPNielsenFGrandjeanPWeihePPolymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese populationEur J Clin Pharmacol2005614914971:CAS:528:DC%2BD2MXptVWks74%3D1602529410.1007/s00228-005-0938-1
DingYXuDZhangXYangHGengTHePGenetic polymorphisms and phenotypic analysis of drug-metabolizing enzyme CYP2C19 in a Li Chinese populationInt J Clin Exp Pathol201581013201132081:CAS:528:DC%2BC1cXlvVKnt7g%3D267225194680464
KubotaTChibaKIshizakiTGenotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese populationClin Pharmacol Ther19966066616661:CAS:528:DyaK2sXms1equg%3D%3D898806810.1016/S0009-9236(96)90214-3
TongTGZhangRLFuGFThe distribution characteristics of CYP2C19 gene polymorphism in Hp positive gastric cancer patientsModern Diag Treat20172811211621171:CAS:528:DC%2BB3MXhsFynsLnI
CaudleKESangkuhlKWhirl-CarrilloMSwenJJHaidarCEKleinTEStandardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and dutch pharmacogenetics Working groupClin Transl Sci20201311161243164718610.1111/cts.12692
SanfordJCGuoYSadeeWWangDRegulatory polymorphisms in CYP2C19 affecting hepatic expressionDrug Metabol Drug Interact201328123301:CAS:528:DC%2BC2cXmtFahsL0%3D23412869375548910.1515/dmdi-2012-0038
ImaJJThomasCDBarbarinoJDestaZVan DriestSLEl RoubyNClinical pharmacogenetics implementation consortium (CPIC) Guideline for CYP2C19 and proton pump inhibitor dosingClin Pharmacol Ther202110961417142310.1002/cpt.2015
Favela-MendozaAFMartinez-CortesGHernandez-ZaragozaMSalazar-FloresJMuñoz-ValleJFMartinez-SevillaVMGenetic variability of CYP2C19 in a Mexican population: Contribution to the knowl-edge of the inheritance pattern of CYP2C19*17 to develop the ultrarapid metabolizer phenotypeJ Genet2015941510.1007/s12041-015-0477-1
BiswasMGlobal distribution of CYP2C19 risk phenotypes affecting safety and effectiveness of medicationsPharmacogenomics J20212121901991:CAS:528:DC%2BB3cXitFagsrbL3308252810.1038/s41397-020-00196-3
JinTZhangXGengTShiXWangLYuanDGenotype-phenotype analysis of CYP2C19 in the Tibetan population and its potential clinical implications in drug therapyMol Med Rep2016133211721231:CAS:528:DC%2BC28XmsFGlsL8%3D26781306476899710.3892/mmr.2016.4776
PangYSWongLPLeeTCMustafaAMMohamedZLangCCGenetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjectsBr J Clin Pharmacol2004583323351:STN:280:DC%2BD2cvit1Sitg%3D%3D1532759510.1111/j.1365-2125.2004.02144.x
OtaTKamadaYHayashidaMIwao-KoizumiKMurataSKinoshitaKCombination analysis in genetic polymorphisms of drug-me-tabolizing enzymes CYP1A2, CYP2C9, CY-P2C19, CYP2D6 and CYP3A5 in the Japanese populationInt J Med Sci20151278821:CAS:528:DC%2BC1cXlsV2jsbo%3D25552922427887910.7150/ijms.10263
RohHKDahlMLTybringGYamadaHChaYNBertilssonLCYP2C19 genotype and phenotype determined by omeprazole in a Korean populationPharmacogenetics1996665475511:CAS:528:DyaK2sXnvFOjtQ%3D%3D901420410.1097/00008571-199612000-00008
OzdilBAkkizHBayramSBekarAAkgöllüESandikçiMInfluence of CYP2C19 functional polymorphism on Helicobacter pylori eradicationTurk J Gastroenterol201021123282053310810.4318/tjg.2010.0043
ChangMDahlMLTybringGGotharsonEBertilssonLUse of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Cau-casians: comparison with S-mephenytoin hy-droxylation phenotype and CYP2C19 genotypePharmacogenetics199553583631:CAS:528:DyaK28XhtFyitrc%3D874740710.1097/00008571-199512000-00004
CPIC® Guideline for Clopidogrel and CYP2C19. 2020. https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19.
WangPFengSBJinYCYP2C19 gene polymorphism and susceptibility to gastric cancer after helicobacter pylori infectionChinese J Nosocomiol2020302170173
SaponeAVairaDTrespidiSPernaFGattaLTampieriAThe clinical role of cytochrome p450 genotypes in Helicobacter pylori managementAm J Gastroenterol2003985101010151:CAS:528:DC%2BD3sXksVentrk%3D1280982110.1111/j.1572-0241.2003.07427.x
SukasemCTunthongRChamnanphonMSantonSJantararoungtongTKoomdeeNCYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factorsPharmgenom Pers Med2013685911:CAS:528:DC%2BC2cXjslartbc%3D
YuMHCChanMCYChungCCYLiAWTYipCYWMakCCYActionable pharmacogenetic variants in Hong Kong Chinese exome sequencing data and projected prescription impact in the Hong Kong populationPLoS Genet202117233600428789178310.1371/journal.pgen.1009323
Jiang X R, Zhang Y G, Lu J, et al. Analysis of CYP2C19 gene polymorphisms in gastrointestinal diseases among Han Chinese in northern China[J]. J Clin Experim Pathol. 2016;32(10):1101–1104,1109.
AhmadTValentovicMARankinGOEffects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamicsBiochem Pharmacol20181531962041:CAS:528:DC%2BC1cXjtFamsr4%3D29458047614836510.1016/j.bcp.2018.02.020
Negovan Anca, Iancu Mihaela, Moldovan Valeriu, Pantea Monica, Sarkany Kinga, Bataga Simona, et al. Influence of MDR1 C3435T, CYP2C19*2 and CYP2C19*3 gene polymorphisms and clinical characteristics on the severity of gastric lesions: a case-control study. J Gastrointest Liver Dis JGLD.2016; 25(2):258–60.
ChenLQinSXieJTangJYangLShenWGenetic poly-morphism analysis of CYP2C19 in Chinese Han populations from different geographic ar-eas of mainland ChinaPharmacogenomics200896917021:CAS:528:DC%2BD1cXmslyjur4%3D1851884810.2217/14622416.9.6.691
GoljanEAbouelhodaMElKaliobyMMJabaanAAlghithiNMeyerBFIdentification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi populationPLoS ONE20221711:CAS:528:DC%2BB38XislWmtrw%3D35089958879723410.1371/journal.pone.0263137
PharmGKB. Drug Label Information and Legend. 2020. https://www.pharmgkb.org
L Chen (473_CR40) 2008; 9
S Yamada (473_CR27) 2001; 36
473_CR56
J Martin (473_CR44) 2020; 22
473_CR51
M Kurzawski (473_CR9) 2006; 62
W Jainan (473_CR49) 2014; 15
Z Zhong (473_CR20) 2017; 23
CO Musumba (473_CR48) 2013; 93
E Goljan (473_CR45) 2022; 17
J Halling (473_CR34) 2005; 61
LJ Zuo (473_CR24) 2012; 16
AF Favela-Mendoza (473_CR35) 2015; 94
XW Yuan (473_CR11) 2022; 27
M Sugimoto (473_CR55) 2005; 22
CS Weldy (473_CR3) 2021; 18
B Gao (473_CR6) 2022; 15
JJ Ima (473_CR13) 2021; 109
473_CR18
473_CR17
473_CR19
I Persson (473_CR38) 1996; 6
WA Kappers (473_CR53) 2001; 177
YS Pang (473_CR29) 2004; 58
T Kubota (473_CR26) 1996; 60
MHC Yu (473_CR46) 2021; 17
Mo Lirong (473_CR57) 2019
B Ozdil (473_CR8) 2010; 21
C Sukasem (473_CR28) 2013; 6
T Ota (473_CR41) 2015; 12
T Ahmad (473_CR4) 2018; 153
J Petrović (473_CR42) 2020; 28
AS Aynacioglu (473_CR36) 1999; 66
A Stajnko (473_CR5) 2022; 159
C Masimirembwa (473_CR39) 1995; 57
MG Scordo (473_CR31) 2004; 50
JC Sanford (473_CR50) 2013; 28
KE Caudle (473_CR16) 2020; 13
AR Shuldiner (473_CR10) 2009; 302
H Wang (473_CR52) 2013; 8
N He (473_CR21) 2002; 58
K Herrlin (473_CR37) 1998; 64
TG Tong (473_CR15) 2017; 28
HK Roh (473_CR25) 1996; 6
473_CR1
P Wang (473_CR14) 2020; 30
J Tian (473_CR47) 2022; 12
YD Zhang (473_CR12) 2020; 58
M Chang (473_CR30) 1995; 5
EA Gaikovitch (473_CR32) 2003; 59
HV Bravo-Villalta (473_CR33) 2005; 61
H Döhner (473_CR2) 2021; 18
A Sapone (473_CR7) 2003; 98
S Suzuki (473_CR54) 2004; 39
Y Ding (473_CR23) 2015; 8
T Jin (473_CR22) 2016; 13
M Biswas (473_CR43) 2021; 21
References_xml – reference: Favela-MendozaAFMartinez-CortesGHernandez-ZaragozaMSalazar-FloresJMuñoz-ValleJFMartinez-SevillaVMGenetic variability of CYP2C19 in a Mexican population: Contribution to the knowl-edge of the inheritance pattern of CYP2C19*17 to develop the ultrarapid metabolizer phenotypeJ Genet2015941510.1007/s12041-015-0477-1
– reference: Jiang X R, Zhang Y G, Lu J, et al. Analysis of CYP2C19 gene polymorphisms in gastrointestinal diseases among Han Chinese in northern China[J]. J Clin Experim Pathol. 2016;32(10):1101–1104,1109.
– reference: OzdilBAkkizHBayramSBekarAAkgöllüESandikçiMInfluence of CYP2C19 functional polymorphism on Helicobacter pylori eradicationTurk J Gastroenterol201021123282053310810.4318/tjg.2010.0043
– reference: TianJZhangJYangZFengSLiSRenSGenetic epidemiology of medication safety and efficacy related variants in the central Han Chinese population with whole genome sequencingFront Pharmacol20221235280256890650910.3389/fphar.2021.790832
– reference: HallingJPetersenMSDamkierPNielsenFGrandjeanPWeihePPolymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese populationEur J Clin Pharmacol2005614914971:CAS:528:DC%2BD2MXptVWks74%3D1602529410.1007/s00228-005-0938-1
– reference: ZhongZHouJLiBZhangQLiuSLiCAnalysis of CYP2C19 genetic polymorphism in a large ethnic hakka population in Southern ChinaMed Sci Monit201723618661921:CAS:528:DC%2BC1MXosFeltL4%3D29288619575786410.12659/MSM.905337
– reference: JinTZhangXGengTShiXWangLYuanDGenotype-phenotype analysis of CYP2C19 in the Tibetan population and its potential clinical implications in drug therapyMol Med Rep2016133211721231:CAS:528:DC%2BC28XmsFGlsL8%3D26781306476899710.3892/mmr.2016.4776
– reference: Bravo-VillaltaHVYamamotoKNakamuraKBayáAOkadaYHoriuchiRGenetic polymor-phism of CYP2C9 and CYP2C19 in a Bolivian population: An investigative and comparative studyEur J Clin Pharmacol2005611791841:CAS:528:DC%2BD2MXktlCntr0%3D1577627710.1007/s00228-004-0890-5
– reference: TongTGZhangRLFuGFThe distribution characteristics of CYP2C19 gene polymorphism in Hp positive gastric cancer patientsModern Diag Treat20172811211621171:CAS:528:DC%2BB3MXhsFynsLnI
– reference: RohHKDahlMLTybringGYamadaHChaYNBertilssonLCYP2C19 genotype and phenotype determined by omeprazole in a Korean populationPharmacogenetics1996665475511:CAS:528:DyaK2sXnvFOjtQ%3D%3D901420410.1097/00008571-199612000-00008
– reference: WeldyCSAshleyEATowards precision medicine in heart failureNat Rev Cardiol202118117457623410867810.1038/s41569-021-00566-9
– reference: AynaciogluASSachseCBozkurtAKortunaySNacakMSchröderTLow frequency of defec-tive alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish pop-ulationClin Pharmacol Ther1999661851921:CAS:528:DyaK1MXlvVOhsLk%3D1046007210.1053/cp.1999.v66.100072001
– reference: HeNYanFXHuangSLWangWXiaoZSLiuZQCYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai populationEur J Clin Pharmacol200258115181:CAS:528:DC%2BD38Xislalurc%3D1195666810.1007/s00228-002-0425-x
– reference: WangPFengSBJinYCYP2C19 gene polymorphism and susceptibility to gastric cancer after helicobacter pylori infectionChinese J Nosocomiol2020302170173
– reference: PangYSWongLPLeeTCMustafaAMMohamedZLangCCGenetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjectsBr J Clin Pharmacol2004583323351:STN:280:DC%2BD2cvit1Sitg%3D%3D1532759510.1111/j.1365-2125.2004.02144.x
– reference: MartinJWilliamsAKKleinMDSriramojuVBMadanSRossiJSFrequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical settingGenet Med20202211601691:CAS:528:DC%2BC1MXhtl2qsLrO3131616910.1038/s41436-019-0611-1
– reference: KappersWAEdwardsRJMurraySBoobisARDiazinon is activated by CYP2C19 in human liverToxicol Appl Pharmacol2001177168761:CAS:528:DC%2BD3MXot12ntrk%3D1170890210.1006/taap.2001.9294
– reference: DöhnerHWeiAHLöwenbergBTowards precision medicine for AMLNat Rev Clin Oncol20211895775903400699710.1038/s41571-021-00509-w
– reference: ScordoMGCaputiAPD'ArrigoCFavaGSpinaEAllele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian populationPharmacol Res2004501952001:CAS:528:DC%2BD2cXks1eku7g%3D1517730910.1016/j.phrs.2004.01.004
– reference: PharmGKB. Drug Label Information and Legend. 2020. https://www.pharmgkb.org/.
– reference: MasimirembwaCBertilssonLJohanssonIHaslerJAIngelman-SundbergMPheno-typing and genotyping of S-mephenytoin hy-droxylase (cytochrome P450 2C19) in a Shona population of ZimbabweClin Pharmacol Ther1995576566611:STN:280:DyaK2MzgtVChtA%3D%3D778126510.1016/0009-9236(95)90228-7
– reference: OtaTKamadaYHayashidaMIwao-KoizumiKMurataSKinoshitaKCombination analysis in genetic polymorphisms of drug-me-tabolizing enzymes CYP1A2, CYP2C9, CY-P2C19, CYP2D6 and CYP3A5 in the Japanese populationInt J Med Sci20151278821:CAS:528:DC%2BC1cXlsV2jsbo%3D25552922427887910.7150/ijms.10263
– reference: SugimotoMFurutaTShiraiNNakamuraAKajimuraMSugimuraHPoor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infectionAliment Pharmacol Ther20052210103310401:CAS:528:DC%2BD2MXhtlWntrrJ1626897910.1111/j.1365-2036.2005.02678.x
– reference: SukasemCTunthongRChamnanphonMSantonSJantararoungtongTKoomdeeNCYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factorsPharmgenom Pers Med2013685911:CAS:528:DC%2BC2cXjslartbc%3D
– reference: YuMHCChanMCYChungCCYLiAWTYipCYWMakCCYActionable pharmacogenetic variants in Hong Kong Chinese exome sequencing data and projected prescription impact in the Hong Kong populationPLoS Genet202117233600428789178310.1371/journal.pgen.1009323
– reference: KubotaTChibaKIshizakiTGenotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese populationClin Pharmacol Ther19966066616661:CAS:528:DyaK2sXms1equg%3D%3D898806810.1016/S0009-9236(96)90214-3
– reference: YamadaSOndaMKatoSMatsudaNMatsuhisaTYamadaNGenetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populationsJ Gastroenterol200136106696721:CAS:528:DC%2BD3MXot1Wmsrs%3D1168647610.1007/s005350170029
– reference: SuzukiSMuroishiYNakanishiIOdaYRelationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancerJ Gastroenterol20043932202301:CAS:528:DC%2BD2cXivVaqsr0%3D1506499810.1007/s00535-003-1281-x
– reference: StajnkoARunkelAAKosjekTSnoj TratnikJMazejDFalnogaIAssessment of susceptibility to phthalate and DINCH exposure through CYP and UGT single nucleotide polymorphismsEnviron Int20221591:CAS:528:DC%2BB38XjvFOju7g%3D3492027710.1016/j.envint.2021.107046
– reference: WangHSongKChenZYuYPoor metabolizers at the cytochrome P450 2C19 loci is at increased risk of developing cancer in Asian populationsPLoS ONE2013881:CAS:528:DC%2BC3sXhsVWhtrjO24015291375491110.1371/journal.pone.0073126
– reference: ImaJJThomasCDBarbarinoJDestaZVan DriestSLEl RoubyNClinical pharmacogenetics implementation consortium (CPIC) Guideline for CYP2C19 and proton pump inhibitor dosingClin Pharmacol Ther202110961417142310.1002/cpt.2015
– reference: ZuoLJGuoTXiaDYJiaLHAllele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populationsGenet Test Mol Biomarkers20121621021081:CAS:528:DC%2BC38XisFWitr0%3D2222455910.1089/gtmb.2011.0084
– reference: LirongMoInvestigation of the current status of Helicobacter pylori infection in the population of Wuzhong City2019Ningxia and analysis of related factorNingxia Medical University
– reference: PharmGKB. CYP2C19 clinical annotations. 2021. https://www.pharmgkb.org/gene/PA124/clinicalAnnotation.
– reference: SaponeAVairaDTrespidiSPernaFGattaLTampieriAThe clinical role of cytochrome p450 genotypes in Helicobacter pylori managementAm J Gastroenterol2003985101010151:CAS:528:DC%2BD3sXksVentrk%3D1280982110.1111/j.1572-0241.2003.07427.x
– reference: MusumbaCOJorgensenASuttonLVan EkerDZhangEO'HaraNCYP2C19*17gain-of-function polymorphism is associated with peptic ulcer diseaseClin Pharmacol Ther20139321952031:CAS:528:DC%2BC3sXhsVars70%3D2326785710.1038/clpt.2012.215
– reference: ShuldinerARO'ConnellJRBlidenKPGandhiARyanKHorensteinRBAssociation of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyJAMA200930288498571:CAS:528:DC%2BD1MXhtVCnt7zL19706858364156910.1001/jama.2009.1232
– reference: GaikovitchEACascorbiIMrozikiewiczPMBrockmöllerJFrötschlRKöpkeKPolymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian populationEur J Clin Pharmacol2003593033121:CAS:528:DC%2BD3sXmt1entLo%3D1287916810.1007/s00228-003-0606-2
– reference: CPIC® Guideline for Clopidogrel and CYP2C19. 2020. https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19.
– reference: DingYXuDZhangXYangHGengTHePGenetic polymorphisms and phenotypic analysis of drug-metabolizing enzyme CYP2C19 in a Li Chinese populationInt J Clin Exp Pathol201581013201132081:CAS:528:DC%2BC1cXlvVKnt7g%3D267225194680464
– reference: GaoBTanTCaoXPanMYangCWangJRelationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactionsBMC Med Genom2022151231:CAS:528:DC%2BB38XmsFWntLY%3D10.1186/s12920-022-01171-6
– reference: PerssonIAklilluERodriguesFBertilssonLIngelman-SundbergMS-mephenytoin hy-droxylation phenotype and CYP2C19 genotype among EthiopiansPharmacogenetics199665215261:CAS:528:DyaK2sXnvFOjtg%3D%3D901420110.1097/00008571-199612000-00005
– reference: Negovan Anca, Iancu Mihaela, Moldovan Valeriu, Pantea Monica, Sarkany Kinga, Bataga Simona, et al. Influence of MDR1 C3435T, CYP2C19*2 and CYP2C19*3 gene polymorphisms and clinical characteristics on the severity of gastric lesions: a case-control study. J Gastrointest Liver Dis JGLD.2016; 25(2):258–60.
– reference: Velmovitsky PE, Bevilacqua T, Alencar P, Cowan D, Morita PP. Convergence of Precision Medicine and Public Health Into Precision Public Health: Toward a Big Data Perspective. Front Public Health. 2021;9:561873.
– reference: ZhangYDDongQWZhangSHGuFZhangYSongHBEffectiveness of eradication regimen based on the bacterial susceptibility and CYP2C19 genotype in children with refractory Helicobacter pylori infectionZhonghua Er Ke Za Zhi202058141451:STN:280:DC%2BB3MbmvV2ktQ%3D%3D31905475Chinese
– reference: BiswasMGlobal distribution of CYP2C19 risk phenotypes affecting safety and effectiveness of medicationsPharmacogenomics J20212121901991:CAS:528:DC%2BB3cXitFagsrbL3308252810.1038/s41397-020-00196-3
– reference: YuanXWYuanSYWuGXWuZXGuanZYGenetic polymorphism of clopidogrel metabolism related gene CYP2C19 gene in Chinese from Foshan area of Guangdong ProvinceHematology2022271105610613611200310.1080/16078454.2022.2121899
– reference: PetrovićJPešićVLauschkeVMFrequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across EuropeEur J Hum Genet202028188943135895510.1038/s41431-019-0480-8
– reference: HerrlinKMasseleAYJandeMAlmCTybringGAbdiYABantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotypeClin Pharmacol Ther1998643914011:STN:280:DyaK1M%2FhsVGgsg%3D%3D979779610.1016/S0009-9236(98)90070-4
– reference: GoljanEAbouelhodaMElKaliobyMMJabaanAAlghithiNMeyerBFIdentification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi populationPLoS ONE20221711:CAS:528:DC%2BB38XislWmtrw%3D35089958879723410.1371/journal.pone.0263137
– reference: AhmadTValentovicMARankinGOEffects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamicsBiochem Pharmacol20181531962041:CAS:528:DC%2BC1cXjtFamsr4%3D29458047614836510.1016/j.bcp.2018.02.020
– reference: KurzawskiMGawrońska-SzklarzBWrześniewskaJSiudaAStarzyńskaTDroździkMEffect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patientsEur J Clin Pharmacol200662108778801:CAS:528:DC%2BD28XhtVeqsb%2FK1691286910.1007/s00228-006-0183-2
– reference: CaudleKESangkuhlKWhirl-CarrilloMSwenJJHaidarCEKleinTEStandardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and dutch pharmacogenetics Working groupClin Transl Sci20201311161243164718610.1111/cts.12692
– reference: JainanWVilaichoneRKEffects of the CYP2C19 genetic polymorphism on gastritis, peptic ulcer disease, peptic ulcer bleeding and gastric cancerAsian Pac J Cancer Prev2014152410957109602560520810.7314/APJCP.2014.15.24.10957
– reference: SanfordJCGuoYSadeeWWangDRegulatory polymorphisms in CYP2C19 affecting hepatic expressionDrug Metabol Drug Interact201328123301:CAS:528:DC%2BC2cXmtFahsL0%3D23412869375548910.1515/dmdi-2012-0038
– reference: ChangMDahlMLTybringGGotharsonEBertilssonLUse of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Cau-casians: comparison with S-mephenytoin hy-droxylation phenotype and CYP2C19 genotypePharmacogenetics199553583631:CAS:528:DyaK28XhtFyitrc%3D874740710.1097/00008571-199512000-00004
– reference: ChenLQinSXieJTangJYangLShenWGenetic poly-morphism analysis of CYP2C19 in Chinese Han populations from different geographic ar-eas of mainland ChinaPharmacogenomics200896917021:CAS:528:DC%2BD1cXmslyjur4%3D1851884810.2217/14622416.9.6.691
– volume: 28
  start-page: 88
  issue: 1
  year: 2020
  ident: 473_CR42
  publication-title: Eur J Hum Genet
  doi: 10.1038/s41431-019-0480-8
– volume: 94
  start-page: 1
  year: 2015
  ident: 473_CR35
  publication-title: J Genet
  doi: 10.1007/s12041-015-0477-1
– volume: 17
  issue: 1
  year: 2022
  ident: 473_CR45
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0263137
– volume: 8
  issue: 8
  year: 2013
  ident: 473_CR52
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0073126
– volume: 58
  start-page: 332
  year: 2004
  ident: 473_CR29
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/j.1365-2125.2004.02144.x
– volume: 28
  start-page: 2116
  issue: 11
  year: 2017
  ident: 473_CR15
  publication-title: Modern Diag Treat
– volume: 159
  year: 2022
  ident: 473_CR5
  publication-title: Environ Int
  doi: 10.1016/j.envint.2021.107046
– volume: 16
  start-page: 102
  issue: 2
  year: 2012
  ident: 473_CR24
  publication-title: Genet Test Mol Biomarkers
  doi: 10.1089/gtmb.2011.0084
– volume: 23
  start-page: 6186
  year: 2017
  ident: 473_CR20
  publication-title: Med Sci Monit
  doi: 10.12659/MSM.905337
– volume: 36
  start-page: 669
  issue: 10
  year: 2001
  ident: 473_CR27
  publication-title: J Gastroenterol
  doi: 10.1007/s005350170029
– volume: 27
  start-page: 1056
  issue: 1
  year: 2022
  ident: 473_CR11
  publication-title: Hematology
  doi: 10.1080/16078454.2022.2121899
– volume: 21
  start-page: 190
  issue: 2
  year: 2021
  ident: 473_CR43
  publication-title: Pharmacogenomics J
  doi: 10.1038/s41397-020-00196-3
– volume: 98
  start-page: 1010
  issue: 5
  year: 2003
  ident: 473_CR7
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2003.07427.x
– volume: 50
  start-page: 195
  year: 2004
  ident: 473_CR31
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2004.01.004
– volume: 61
  start-page: 491
  year: 2005
  ident: 473_CR34
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s00228-005-0938-1
– volume: 12
  year: 2022
  ident: 473_CR47
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2021.790832
– volume: 59
  start-page: 303
  year: 2003
  ident: 473_CR32
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s00228-003-0606-2
– volume: 13
  start-page: 2117
  issue: 3
  year: 2016
  ident: 473_CR22
  publication-title: Mol Med Rep
  doi: 10.3892/mmr.2016.4776
– volume: 58
  start-page: 15
  issue: 1
  year: 2002
  ident: 473_CR21
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s00228-002-0425-x
– volume: 66
  start-page: 185
  year: 1999
  ident: 473_CR36
  publication-title: Clin Pharmacol Ther
  doi: 10.1053/cp.1999.v66.100072001
– ident: 473_CR17
– volume: 17
  issue: 2
  year: 2021
  ident: 473_CR46
  publication-title: PLoS Genet
  doi: 10.1371/journal.pgen.1009323
– ident: 473_CR51
  doi: 10.15403/jgld.2014.1121.252.mdr
– volume: 61
  start-page: 179
  year: 2005
  ident: 473_CR33
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s00228-004-0890-5
– ident: 473_CR56
– volume: 30
  start-page: 170
  issue: 2
  year: 2020
  ident: 473_CR14
  publication-title: Chinese J Nosocomiol
– volume: 18
  start-page: 745
  issue: 11
  year: 2021
  ident: 473_CR3
  publication-title: Nat Rev Cardiol
  doi: 10.1038/s41569-021-00566-9
– volume-title: Investigation of the current status of Helicobacter pylori infection in the population of Wuzhong City
  year: 2019
  ident: 473_CR57
– ident: 473_CR1
  doi: 10.3389/fpubh.2021.561873
– volume: 60
  start-page: 661
  issue: 6
  year: 1996
  ident: 473_CR26
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/S0009-9236(96)90214-3
– volume: 22
  start-page: 1033
  issue: 10
  year: 2005
  ident: 473_CR55
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/j.1365-2036.2005.02678.x
– volume: 8
  start-page: 13201
  issue: 10
  year: 2015
  ident: 473_CR23
  publication-title: Int J Clin Exp Pathol
– volume: 177
  start-page: 68
  issue: 1
  year: 2001
  ident: 473_CR53
  publication-title: Toxicol Appl Pharmacol
  doi: 10.1006/taap.2001.9294
– volume: 58
  start-page: 41
  issue: 1
  year: 2020
  ident: 473_CR12
  publication-title: Zhonghua Er Ke Za Zhi
– volume: 62
  start-page: 877
  issue: 10
  year: 2006
  ident: 473_CR9
  publication-title: Eur J Clin Pharmacol
  doi: 10.1007/s00228-006-0183-2
– volume: 18
  start-page: 577
  issue: 9
  year: 2021
  ident: 473_CR2
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-021-00509-w
– volume: 12
  start-page: 78
  year: 2015
  ident: 473_CR41
  publication-title: Int J Med Sci
  doi: 10.7150/ijms.10263
– volume: 15
  start-page: 10957
  issue: 24
  year: 2014
  ident: 473_CR49
  publication-title: Asian Pac J Cancer Prev
  doi: 10.7314/APJCP.2014.15.24.10957
– volume: 57
  start-page: 656
  year: 1995
  ident: 473_CR39
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/0009-9236(95)90228-7
– volume: 64
  start-page: 391
  year: 1998
  ident: 473_CR37
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/S0009-9236(98)90070-4
– ident: 473_CR18
– volume: 5
  start-page: 358
  year: 1995
  ident: 473_CR30
  publication-title: Pharmacogenetics
  doi: 10.1097/00008571-199512000-00004
– volume: 15
  start-page: 23
  issue: 1
  year: 2022
  ident: 473_CR6
  publication-title: BMC Med Genom
  doi: 10.1186/s12920-022-01171-6
– volume: 6
  start-page: 521
  year: 1996
  ident: 473_CR38
  publication-title: Pharmacogenetics
  doi: 10.1097/00008571-199612000-00005
– volume: 21
  start-page: 23
  issue: 1
  year: 2010
  ident: 473_CR8
  publication-title: Turk J Gastroenterol
  doi: 10.4318/tjg.2010.0043
– volume: 6
  start-page: 547
  issue: 6
  year: 1996
  ident: 473_CR25
  publication-title: Pharmacogenetics
  doi: 10.1097/00008571-199612000-00008
– volume: 93
  start-page: 195
  issue: 2
  year: 2013
  ident: 473_CR48
  publication-title: Clin Pharmacol Ther
  doi: 10.1038/clpt.2012.215
– volume: 109
  start-page: 1417
  issue: 6
  year: 2021
  ident: 473_CR13
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt.2015
– volume: 6
  start-page: 85
  year: 2013
  ident: 473_CR28
  publication-title: Pharmgenom Pers Med
– volume: 22
  start-page: 160
  issue: 1
  year: 2020
  ident: 473_CR44
  publication-title: Genet Med
  doi: 10.1038/s41436-019-0611-1
– ident: 473_CR19
– volume: 39
  start-page: 220
  issue: 3
  year: 2004
  ident: 473_CR54
  publication-title: J Gastroenterol
  doi: 10.1007/s00535-003-1281-x
– volume: 13
  start-page: 116
  issue: 1
  year: 2020
  ident: 473_CR16
  publication-title: Clin Transl Sci
  doi: 10.1111/cts.12692
– volume: 9
  start-page: 691
  year: 2008
  ident: 473_CR40
  publication-title: Pharmacogenomics
  doi: 10.2217/14622416.9.6.691
– volume: 28
  start-page: 23
  issue: 1
  year: 2013
  ident: 473_CR50
  publication-title: Drug Metabol Drug Interact
  doi: 10.1515/dmdi-2012-0038
– volume: 302
  start-page: 849
  issue: 8
  year: 2009
  ident: 473_CR10
  publication-title: JAMA
  doi: 10.1001/jama.2009.1232
– volume: 153
  start-page: 196
  year: 2018
  ident: 473_CR4
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2018.02.020
SSID ssj0041235
Score 2.3611755
Snippet Background Poor metabolizer (PM) status of CYP2C19 can be a predisposing factor for developing gastric cancer in  H. pylori -infected patients. It is unclear...
Poor metabolizer (PM) status of CYP2C19 can be a predisposing factor for developing gastric cancer in H. pylori-infected patients. It is unclear whether PM...
Poor metabolizer (PM) status of CYP2C19 can be a predisposing factor for developing gastric cancer in H. pylori-infected patients. It is unclear whether PM...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 705
SubjectTerms Drug Safety and Pharmacovigilance
Medicine
Pharmacotherapy
Pharmacy
Title CYP2C19 gene polymorphism in Ningxia
URI https://link.springer.com/article/10.1007/s43440-023-00473-5
https://www.ncbi.nlm.nih.gov/pubmed/36913175
https://www.proquest.com/docview/2786516917
Volume 75
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxELYglRAXRMsrlKJFqnohRru2106ObaCqkFr1kEppLyvba5dIaAMkkQi_vuPHPkqgolxWkTXZTfYbj-fhz4PQPklLxZU22MpSYSaZxpKmFqfMcGVKrrl1Fd3TM35ywT5P82m7T9ezS5bqg_71R17J_6AKY4CrY8neA9nmpjAAnwFfuALCcP0njMeX52ScjVwbZOPaLUAcD6_Ntb2YVYBxdf1zJrve53l7TrXHJhYMmpkfc8dXX1p-2DTULy5X1feOIjVp5o9y3dj1q_nKi0axmEogtN3ydCuV-Fsyss2HdeykoAxDKBVKKsaPEVjZcM5Dx7fauIa2KFGJaMdSijTvLLoiMEk37HnYwrFg1JWg_S9OmaA4b1evZk9hc_6yFy5AuPDCRf4QbREIIkgPbR0eHx2d1Ss1czxhT5iNfyaSqjy1cuORtx2XjWhko5LuHZTJU_QkRhbJYVCTbfTAVDvo0WncO7GDDiL660EyaUl3i0FykHT0Yv0M7Ue1SpxaJV21SmZVEtXqObo4_jQZn-DYTANrysQSK6uE1UILqSS4zaVwrq9wOUVrqGCSi9SMpDHWkmFpiMqYVLm2o5Iq8PpzQV-gXjWvzCuUKHAjs5EdCs1cWZ0PqYWgnxKhreR5Sfooq99UoeNJ867hydfi7xj10fvmO9_COSt3Sr-rASjAHLoal6zMfLUoiBhyV_rNRB-9DMg096Mw7NzlPhrUUBVxNi_ueNjr-4nvosft3HqDessfK7MHjutSvY36dwO9XI7H
linkProvider Library Specific Holdings
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CYP2C19+gene+polymorphism+in+Ningxia&rft.jtitle=Pharmacological+reports&rft.au=Yang%2C+Zhen&rft.au=Xie%2C+Yunqian&rft.au=Zhang%2C+Daya&rft.au=Zou%2C+Yan&rft.date=2023-06-01&rft.pub=Springer+International+Publishing&rft.issn=1734-1140&rft.eissn=2299-5684&rft.volume=75&rft.issue=3&rft.spage=705&rft.epage=714&rft_id=info:doi/10.1007%2Fs43440-023-00473-5&rft.externalDocID=10_1007_s43440_023_00473_5
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1734-1140&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1734-1140&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1734-1140&client=summon